Literature DB >> 18622600

Slower onset of vasodilating action of brain natriuretic peptide (BNP) compared to atrial natriuretic peptide (ANP) in human forearm resistant vessels.

Hironobu Minami1, Takanori Yasu, Tatsuya Tagawa, Ken Yamakawa, Shinichiro Ueda.   

Abstract

PURPOSE: To investigate possible differences in the time course of vasodilating effects of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) in humans.
METHODS: We measured forearm blood flow (FBF) by strain gauge plethymography and cyclic GMP spillover during and after intra-arterial infusions of BNP and ANP at 16.2 pmol/min for 30 min in healthy subjects.
RESULTS: The steady-state responses of FBF and cyclic GMP to the infusion were achieved approximately 20 min after commencement of the infusion of BNP, but within 5 min for ANP, with similar magnitudes of maximum responses. These parameters more slowly returned to the baseline value after withdrawal of the BNP infusion than after the ANP infusion.
CONCLUSION: The onset and disappearance of the guanylate cyclase-stimulating and vasodilating effects of BNP were significantly slower than those of ANP. This differing mode of vasodilator action may be relevant to the therapeutic use of natriuretic peptides.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18622600     DOI: 10.1007/s00228-008-0516-4

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  18 in total

Review 1.  Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions.

Authors:  Lincoln R Potter; Sarah Abbey-Hosch; Deborah M Dickey
Journal:  Endocr Rev       Date:  2005-11-16       Impact factor: 19.871

2.  Extracellular domain-IgG fusion proteins for three human natriuretic peptide receptors. Hormone pharmacology and application to solid phase screening of synthetic peptide antisera.

Authors:  B D Bennett; G L Bennett; R V Vitangcol; J R Jewett; J Burnier; W Henzel; D G Lowe
Journal:  J Biol Chem       Date:  1991-12-05       Impact factor: 5.157

3.  The primary structure of a plasma membrane guanylate cyclase demonstrates diversity within this new receptor family.

Authors:  S Schulz; S Singh; R A Bellet; G Singh; D J Tubb; H Chin; D L Garbers
Journal:  Cell       Date:  1989-09-22       Impact factor: 41.582

4.  Differing biological effects of equimolar atrial and brain natriuretic peptide infusions in normal man.

Authors:  P J Hunt; E A Espiner; M G Nicholls; A M Richards; T G Yandle
Journal:  J Clin Endocrinol Metab       Date:  1996-11       Impact factor: 5.958

5.  Cyclic GMP elevation by 5-hydroxytryptamine is due to nitric oxide derived from endogenous nitrosothiol in NG108-15 cells.

Authors:  T Arima; Y Ohshima; T Mizuno; Y Kitamura; T Segawa; Y Nomura
Journal:  Biochem Biophys Res Commun       Date:  1996-10-14       Impact factor: 3.575

6.  Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group.

Authors:  W S Colucci; U Elkayam; D P Horton; W T Abraham; R C Bourge; A D Johnson; L E Wagoner; M M Givertz; C S Liang; M Neibaur; W H Haught; T H LeJemtel
Journal:  N Engl J Med       Date:  2000-07-27       Impact factor: 91.245

7.  Direct comparison of relaxation and cGMP production in human coronary by-pass grafts in response to stimulation with natriuretic peptides and a nitric oxide donor.

Authors:  Angelika Hammerer-Lercher; Johann Fersterer; Sigrid Holzmann; Johannes Bonatti; Elfriede Ruttmann; Daniel Hoefer; Johannes Mair; Bernd Puschendorf
Journal:  Clin Sci (Lond)       Date:  2006-09       Impact factor: 6.124

8.  Effects of brain natriuretic peptide on forearm vasculature: comparison with atrial natriuretic peptide.

Authors:  K van der Zander; A J Houben; A A Kroon; P W de Leeuw
Journal:  Cardiovasc Res       Date:  1999-12       Impact factor: 10.787

9.  Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide.

Authors:  S Suga; K Nakao; K Hosoda; M Mukoyama; Y Ogawa; G Shirakami; H Arai; Y Saito; Y Kambayashi; K Inouye
Journal:  Endocrinology       Date:  1992-01       Impact factor: 4.736

10.  Differing metabolism and bioactivity of atrial and brain natriuretic peptides in essential hypertension.

Authors:  G B Pidgeon; A M Richards; M G Nicholls; E A Espiner; T G Yandle; C Frampton
Journal:  Hypertension       Date:  1996-04       Impact factor: 10.190

View more
  1 in total

Review 1.  Intra-Target Microdosing (ITM): A Novel Drug Development Approach Aimed at Enabling Safer and Earlier Translation of Biological Insights Into Human Testing.

Authors:  T Burt; R J Noveck; D B MacLeod; A T Layton; M Rowland; G Lappin
Journal:  Clin Transl Sci       Date:  2017-04-18       Impact factor: 4.689

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.